Fluvoxamine

Fluvoxamine is a selective serotonin reuptake inhibitor, a family of antidepressants that increase the amount of serotonin available between nerve cells ^[1][2]. Chemically it is a fluorinated compound with the molecular formula C15H21F3N2O, and it is a potent and highly selective blocker of the serotonin transporter, favouring it roughly a hundredfold over the transporter for noradrenaline ^[1]. A feature that sets it apart from other SSRIs is its strong action at the sigma-1 receptor, a distinct protein involved in cellular stress responses, where it behaves as an agonist ^[1][3]. It is taken by mouth, has a half-life of around half a day that lengthens with repeated dosing, and is cleared through the liver ^[2].

Fluvoxamine was developed by the pharmaceutical firm Kali-Duphar, later part of Solvay, and was first introduced in Switzerland in the early 1980s under the name Floxyfral, making it one of the first SSRIs to be marketed anywhere ^[1]. It later reached the United States in 1994 under the brand name Luvox, where it was notable as the first SSRI approved specifically for obsessive-compulsive disorder, including in children ^[1]. It has since been sold under several names in different countries and is available as a generic ^[1].

The drug is used chiefly for obsessive-compulsive disorder and major depression, and it is also prescribed for social anxiety disorder, panic disorder, and related anxiety conditions ^[1][2]. A review of its pharmacology concluded that it is a well-tolerated option for panic disorder and social anxiety, while cautioning that its extensive interactions with liver enzymes can limit its use in older people or those taking many other drugs ^[2]. Beyond psychiatry, interest in fluvoxamine widened during the COVID-19 pandemic; a large randomised platform trial in high-risk outpatients found that early treatment reduced the need for emergency care or hospitalisation, an effect often attributed to its sigma-1 activity and possible anti-inflammatory action rather than to its serotonin effects ^[4]. Regulators nonetheless considered the overall evidence insufficient to authorise it for that purpose ^[1].

As with other SSRIs, the more common side effects include nausea, sleep disturbance, headache, and sexual difficulties, and combining it with other serotonin-boosting drugs can risk serotonin syndrome ^[1][2]. Its most distinctive practical concern is its effect on drug metabolism; fluvoxamine strongly inhibits the liver enzyme CYP1A2 and also CYP2C19, so it can raise blood levels of substances processed by those enzymes, including caffeine, the antipsychotic clozapine, and theophylline ^[1][2]. For this reason it is prescribed with particular care when other medications are involved ^[2]. It is supplied as tablets and extended-release capsules ^[1].

Fluvoxamine is an SSRI and a potent inhibitor of CYP1A2 and CYP2C19, giving it a high potential for serious drug interactions (for example with caffeine, theophylline, tizanidine, and clozapine). It shares class effects such as nausea, somnolence, sexual dysfunction, and a discontinuation syndrome, and can precipitate serotonin syndrome with other serotonergic drugs or MAOIs. It also carries the antidepressant boxed warning for increased suicidal ideation in youth, so mood should be watched early in use.

Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19, making it one of the more interactive SSRIs. When duloxetine was coadministered with fluvoxamine, the duloxetine area under the plasma concentration curve increased 460% and peak concentration increased 141%, representing a strong pharmacokinetic interaction via CYP1A2 inhibition ^[24]. Fluvoxamine increases plasma concentrations of drugs metabolized by CYP1A2 and CYP2C19 ^[25]. These are pharmacokinetic interactions; fluvoxamine decreases the clearance of victim drugs. Fluvoxamine itself also carries serotonin syndrome risk when combined with other serotonergic agents, though this pharmacodynamic concern is less emphasized in the literature than its CYP inhibition profile. Interactions with CYP3A4 substrates and with drugs that fluvoxamine does not inhibit via the CYP system remain largely unexplored.

Checking a whole stack? Run it through interactions + stacks.

Fluvoxamine was developed by the Dutch pharmaceutical company Kali-Duphar, later part of Solvay, and reached the market in the early 1980s, making it one of the very first selective serotonin reuptake inhibitors to be introduced anywhere in the world. It was first launched in Switzerland in 1983 and subsequently spread across Europe, but it was not approved in the United States until 1994, where it was cleared specifically for obsessive-compulsive disorder rather than depression. Over the following decades it became a mainstay for OCD and several anxiety disorders and gained a reputation for its many drug interactions, owing to its potent inhibition of the liver enzyme CYP1A2.

Interest in the molecule broadened considerably after research identified it as a high-affinity agonist at the sigma-1 receptor, a chaperone protein implicated in cellular stress and inflammation. This sigma-1 activity brought fluvoxamine unexpected attention during the COVID-19 pandemic, when it was investigated as a possible early treatment to reduce clinical deterioration. Its long clinical track record and unusual pharmacology have kept it a subject of active study well beyond its original psychiatric uses.

Fluvoxamine is well regarded as an effective and durable treatment for obsessive-compulsive disorder, a condition where its long history gives clinicians considerable confidence. Beyond psychiatry, it has earned a distinctive scientific profile because of its potent sigma-1 receptor activity, a feature that sets it apart from most other SSRIs and has fueled research into anti-inflammatory and neuroprotective applications.

Its investigation as a low-cost, widely available candidate for early COVID-19 drew global interest, though the evidence there remained of low certainty and did not establish it as a standard therapy. Like other SSRIs it is generally well tolerated over long-term use, and its efficacy for anxiety disorders is solidly established. Its main practical drawback is a notable potential for drug interactions through CYP1A2 inhibition, which requires attention when it is combined with other medicines. On balance it is a proven, intriguing molecule whose pharmacology continues to surprise researchers.